Ufp Technologies Inc (UFPT) Stock Analysis and Metrics

Ufp Technologies

NASDAQ: UFPT

$236.60 ▲ +0.39 (+0.17%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.82 Bn

P/E26.58

P/S3.00

Div. Yield0.00

ROIC (Qtr)0.02

Total Debt (Qtr)150.11 Mn

Revenue Growth (1y) (Qtr)4.09

Add ratio to table…

About

UFP Technologies, Inc. is a contract development and manufacturing organization that specializes in single use and single patient medical devices. The company serves as a vital link in the medical device supply chain and acts as an outsourcing partner to many of the world's leading medical device manufacturers. Its products are used in minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. UFP Technologies…

Investment Thesis

▲ Bull case

The medical segment continues to show robust expansion with revenue up 5.9% year over year driven by double digit growth in robotic surgery patient surfaces and support and interventional and surgical product lines. This performance reflects successful execution of the four new program launches that are already receiving requests from customers to double capacity signaling strong demand and validating the company’s product development pipeline. The shift toward higher margin medical offerings reduces reliance on the softer non medical business and positions UFPT to benefit from secular growth trends in minimally invasive surgery and advanced wound care. As these programs move from start up to volume production the contribution to earnings will become more pronounced in the second half of fiscal year 2026 and beyond.
Capacity expansion in the Dominican Republic is being funded through co investment with key customers which lowers capital intensity for UFPT while securing long term supply agreements. The addition of a sixth building in La Romana and a third building in Santiago will increase low cost country footprint by approximately one sixth each providing scalable platforms for robotic surgery and patient surfaces support respectively. This infrastructure investment aligns with customer requests for increased capacity and supports the company’s strategy to shift production to lower cost regions thereby improving gross margins over time. The fact that customers are willing to co invest underscores confidence in UFPT’s operational execution and future growth prospects.
Operating leverage is improving as evidenced by the rise in gross margin to 28.8% from 28.5% a year earlier despite ongoing labor inefficiencies at the AJR facility. The margin expansion was aided by a more than 200% increase in revenue from the Santiago operation which allowed the company to spread fixed overhead over a larger base. As labor inefficiencies at AJR diminish and production shifts to the more efficient Santiago site the cost of sales is expected to improve further driving incremental margin expansion. The combination of higher margin medical sales and better asset utilization creates a pathway to sustained adjusted operating margin improvement beyond the current 16.7% level.
The balance sheet remains strong with a leverage ratio of approximately 1.14x after paying down roughly $4 million of debt in the first quarter and generating $3.2 million of cash from operations. This low leverage provides financial flexibility to fund additional capacity investments pursue selective acquisitions and weather any short term volatility in raw material costs. The disciplined approach to mergers and acquisitions highlighted by management indicates that any future deals will be vetted for strategic fit culture and value creation reducing the risk of overpayment. The ability to generate internal cash while maintaining a conservative debt profile supports the outlook for continued shareholder value creation through both organic and inorganic growth.
Leadership transition appears well managed with outgoing CEO Jeff Bailly staying on as executive chair for a year to support incoming CEO Mitch Rock who is described as well prepared and respected by the team vendor partners and blue chip customers. This continuity reduces execution risk during the changeover and ensures that strategic initiatives such as the new program ramps capacity expansion and M&A pipeline remain on track. The deep bench of managers noted by management suggests that operational knowledge is widely distributed reducing dependence on any single individual. A stable leadership environment combined with clear strategic priorities should enable the company to meet its growth targets and deliver consistent performance to shareholders.

The medical segment continues to show robust expansion with revenue up 5.9% year over year driven by double digit growth in robotic surgery patient surfaces and support and interventional and surgical product lines. This performance reflects successful execution of the four new program launches that are already receiving requests from customers to double capacity signaling strong demand and validating the company’s product development pipeline. The shift toward higher margin medical offerings reduces reliance on the softer non medical business and positions UFPT to benefit from secular growth trends in minimally invasive surgery and advanced wound care. As these programs move from start up to volume production the contribution to earnings will become more pronounced in the second half of fiscal year 2026 and beyond.
Capacity expansion in the Dominican Republic is being funded through co investment with key customers which lowers capital intensity for UFPT while securing long term supply agreements. The addition of a sixth building in La Romana and a third building in Santiago will increase low cost country footprint by approximately one sixth each providing scalable platforms for robotic surgery and patient surfaces support respectively. This infrastructure investment aligns with customer requests for increased capacity and supports the company’s strategy to shift production to lower cost regions thereby improving gross margins over time. The fact that customers are willing to co invest underscores confidence in UFPT’s operational execution and future growth prospects.
Operating leverage is improving as evidenced by the rise in gross margin to 28.8% from 28.5% a year earlier despite ongoing labor inefficiencies at the AJR facility. The margin expansion was aided by a more than 200% increase in revenue from the Santiago operation which allowed the company to spread fixed overhead over a larger base. As labor inefficiencies at AJR diminish and production shifts to the more efficient Santiago site the cost of sales is expected to improve further driving incremental margin expansion. The combination of higher margin medical sales and better asset utilization creates a pathway to sustained adjusted operating margin improvement beyond the current 16.7% level.
The balance sheet remains strong with a leverage ratio of approximately 1.14x after paying down roughly $4 million of debt in the first quarter and generating $3.2 million of cash from operations. This low leverage provides financial flexibility to fund additional capacity investments pursue selective acquisitions and weather any short term volatility in raw material costs. The disciplined approach to mergers and acquisitions highlighted by management indicates that any future deals will be vetted for strategic fit culture and value creation reducing the risk of overpayment. The ability to generate internal cash while maintaining a conservative debt profile supports the outlook for continued shareholder value creation through both organic and inorganic growth.
Leadership transition appears well managed with outgoing CEO Jeff Bailly staying on as executive chair for a year to support incoming CEO Mitch Rock who is described as well prepared and respected by the team vendor partners and blue chip customers. This continuity reduces execution risk during the changeover and ensures that strategic initiatives such as the new program ramps capacity expansion and M&A pipeline remain on track. The deep bench of managers noted by management suggests that operational knowledge is widely distributed reducing dependence on any single individual. A stable leadership environment combined with clear strategic priorities should enable the company to meet its growth targets and deliver consistent performance to shareholders.

▼ Bear case

The non medical business continues to deteriorate with a 15% decline in sales driven primarily by the phase out of automotive sales which management acknowledges will become the new normal. This structural decline removes a historically stable revenue stream and places greater pressure on the medical segment to offset the loss. While the company is redirecting resources toward higher growth areas the transition may take time and could weigh on overall revenue growth if medical expansion does not fully compensate. The reliance on a shrinking non medical base increases the volatility of total sales and may limit the ability to achieve top line guidance without stronger than expected medical performance.
Start up costs associated with the four simultaneous program launches are weighing on near term earnings per share as management noted that EPS grew more slowly than revenue due to these expenses. Although the programs are expected to become meaningful contributors in the second half of fiscal year 2026 the initial phase involves hiring training and overhead that depresses margins. If the ramp up of volume is slower than anticipated the drag on profitability could persist longer than forecast potentially leading to missed earnings expectations. Investors may be underestimating the duration and magnitude of these start up headwinds which could keep adjusted operating margin below target levels for several quarters.
Labor inefficiencies at the AJR facility in Illinois remain a persistent challenge despite management’s optimism about improvement through the shift of work to Santiago. The transfer of three major programs is ongoing with one program still in the protracted PPAP and protocol phase which could take more than a year to become a meaningful contributor. Until the transfer is complete the facility will continue to operate with a less efficient workforce requiring overtime and increasing cost of sales. Any delay in completing the transfer or in achieving expected efficiency gains at Santiago could prolong the margin pressure from AJR and hinder the company’s ability to leverage its Illinois footprint effectively.
The wound care segment is experiencing a temporary slowdown due to excess inventory at two major customers which management estimates will impact sales for roughly three quarters. While they view this as an inventory issue the duration and severity of the slowdown could be longer if customers maintain higher inventory levels than anticipated or if market demand for wound care products weakens. A prolonged wound care downturn would offset gains from other medical subsegments and could delay the overall recovery of the medical business. The company’s long term bullishness on wound care relies on a resurgence of interest that may not materialize as quickly as hoped exposing the segment to further downside risk.
Raw material cost volatility stemming from the Iran conflict and fluctuating oil prices introduces uncertainty into the company’s cost structure despite management’s expectation of passing through increases to customers. While effective tariffs are currently net down the ability to fully offset commodity price spikes depends on customer pricing power and contract terms. If raw material inflation outpaces the ability to raise selling prices gross margin could contract eroding the modest improvement seen in the first quarter. This external cost pressure adds a layer of risk that is not fully captured in the current guidance and could affect profitability if the geopolitical situation deteriorates.

The non medical business continues to deteriorate with a 15% decline in sales driven primarily by the phase out of automotive sales which management acknowledges will become the new normal. This structural decline removes a historically stable revenue stream and places greater pressure on the medical segment to offset the loss. While the company is redirecting resources toward higher growth areas the transition may take time and could weigh on overall revenue growth if medical expansion does not fully compensate. The reliance on a shrinking non medical base increases the volatility of total sales and may limit the ability to achieve top line guidance without stronger than expected medical performance.
Start up costs associated with the four simultaneous program launches are weighing on near term earnings per share as management noted that EPS grew more slowly than revenue due to these expenses. Although the programs are expected to become meaningful contributors in the second half of fiscal year 2026 the initial phase involves hiring training and overhead that depresses margins. If the ramp up of volume is slower than anticipated the drag on profitability could persist longer than forecast potentially leading to missed earnings expectations. Investors may be underestimating the duration and magnitude of these start up headwinds which could keep adjusted operating margin below target levels for several quarters.
Labor inefficiencies at the AJR facility in Illinois remain a persistent challenge despite management’s optimism about improvement through the shift of work to Santiago. The transfer of three major programs is ongoing with one program still in the protracted PPAP and protocol phase which could take more than a year to become a meaningful contributor. Until the transfer is complete the facility will continue to operate with a less efficient workforce requiring overtime and increasing cost of sales. Any delay in completing the transfer or in achieving expected efficiency gains at Santiago could prolong the margin pressure from AJR and hinder the company’s ability to leverage its Illinois footprint effectively.
The wound care segment is experiencing a temporary slowdown due to excess inventory at two major customers which management estimates will impact sales for roughly three quarters. While they view this as an inventory issue the duration and severity of the slowdown could be longer if customers maintain higher inventory levels than anticipated or if market demand for wound care products weakens. A prolonged wound care downturn would offset gains from other medical subsegments and could delay the overall recovery of the medical business. The company’s long term bullishness on wound care relies on a resurgence of interest that may not materialize as quickly as hoped exposing the segment to further downside risk.
Raw material cost volatility stemming from the Iran conflict and fluctuating oil prices introduces uncertainty into the company’s cost structure despite management’s expectation of passing through increases to customers. While effective tariffs are currently net down the ability to fully offset commodity price spikes depends on customer pricing power and contract terms. If raw material inflation outpaces the ability to raise selling prices gross margin could contract eroding the modest improvement seen in the first quarter. This external cost pressure adds a layer of risk that is not fully captured in the current guidance and could affect profitability if the geopolitical situation deteriorates.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Concentration Risk Benchmark Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Concentration Risk Benchmark Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password